Manchester Techbio Spin-Out Imperagen Raises £5 Million (6.7 Million USD) Seed Round to Scale Closed-Loop Quantum Biocatalysis Platform - Quantum Computing Report

Skip to content

GQINewsNews – RecentNews Archive 2025News Archive 2024News Archive 2023News Archive 2022News Archive, 2021News Archive, 2020News Archive, 2019News Archive, 2018News Archive, 2015-2017AnalysisQnalysisPlayersPublic CompaniesPrivate/Startup CompaniesUniversitiesGovernment/Non-ProfitVenture CapitalVenture Capital – Sorted by Quantum CompanyResourcesConferencesToolsOther Websites and Industry AssociationsEducationBooksScorecardsGate Level Software PlatformsIBM Qiskit, Rigetti Forest, Microsoft QDK, Project QReview of the Cirq Quantum Software FrameworkQubit Implementation DashboardQubit CountQubit QualityQubit TechnologySoftware/Startup PartnersCloud Platform Hardware PartnersPodcastsAboutQCR Alerts Sign-Up FormAdvertising InquiriesQCR in the NewsContactPrivacy PolicyMembership

Manchester Techbio Spin-Out Imperagen Raises £5 Million (6.7 Million USD) Seed Round to Scale Closed-Loop Quantum Biocatalysis Platform

Imperagen Ltd, a Manchester-based techbio innovator accelerating industrial enzyme engineering, has successfully finalized a £5 million (6.7 million USD) seed funding round. The investment loop was led by regional deep-tech backer PXN Ventures—deploying capital via the GMC Life Sciences Fund and the Northern Powerhouse Investment Fund II (NPIF II)—with continued participation from existing venture backers IQ Capital and Northern Gritstone. The fresh influx of capital brings Imperagen’s total financing footprint to £8.5 million ($11.44 million USD), providing an 18-month cash runway to expand its automated wet-lab infrastructure, scale its data science engineering group, and drive market commercialization across the global biopharma, personal care, and fine chemical sectors.